MASSACHUSETTS EYE AND EAR INFIRMARY
BOSTON, MA
What changed
NIH K23 · $0.2M · Dissecting temporal and spatial dynamics of immunotherapy resistance
Mar 2025Grant renewalMar 20, 2025Source filing (opens the source filing in a new tab)
Momentum
Momentum 16 out of 100, unchanged since the last recompute.
Little recent filing activity, or the events on file have decayed.
Runway (estimate)
No disclosed raise on file, so there is nothing to model from.
Stage
Grant-only
The furthest-along thing in the public record. Not a projection.
Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.
Grant to raise
Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.
- Grant
K23 · $174k · non-dilutive
Apr 1, 2021MASSACHUSETTS EYE AND EAR INFIRMARY · PI FADEN, DANIEL · NIDCR · award ends Mar 31, 2027 · Dissecting temporal and spatial dynamics of immunotherapy resistance
NIH RePORTER · NIH RePORTER 11060027 (opens the source filing in a new tab)
Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources